0.5725
2.19%
-0.0155
前日終値:
$0.588
開ける:
$0.571
24時間の取引高:
97,266
Relative Volume:
0.21
時価総額:
$24.28M
収益:
$1.38M
当期純損益:
$-179.05M
株価収益率:
-0.0805
EPS:
-7.11
ネットキャッシュフロー:
$-155.03M
1週間 パフォーマンス:
+10.51%
1か月 パフォーマンス:
+4.72%
6か月 パフォーマンス:
-71.39%
1年 パフォーマンス:
-85.25%
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
名前
Bioxcel Therapeutics Inc
セクター
電話
203-643-8060
住所
555 LONG WHARF DRIVE, NEW HAVEN, CT
BTAI を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
BTAI | 0.5701 | 24.28M | 1.38M | -179.05M | -155.03M | -7.11 |
VRTX | 449.47 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 746.00 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 594.28 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 245.84 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.00 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-08-15 | ダウングレード | Mizuho | Buy → Neutral |
2023-07-17 | ダウングレード | Guggenheim | Buy → Neutral |
2023-03-10 | ダウングレード | Jefferies | Buy → Hold |
2022-12-01 | アップグレード | Goldman | Sell → Neutral |
2022-07-07 | 開始されました | Mizuho | Buy |
2022-04-06 | 繰り返されました | BofA Securities | Buy |
2021-11-15 | ダウングレード | Goldman | Neutral → Sell |
2021-04-09 | 開始されました | Berenberg | Buy |
2021-02-01 | 開始されました | UBS | Buy |
2020-10-30 | 開始されました | Goldman | Buy |
2020-09-02 | 開始されました | Jefferies | Buy |
2020-08-17 | 繰り返されました | H.C. Wainwright | Buy |
2020-07-08 | 繰り返されました | H.C. Wainwright | Buy |
2020-06-04 | 開始されました | Guggenheim | Buy |
2020-04-01 | 開始されました | BofA/Merrill | Buy |
2020-02-26 | 繰り返されました | H.C. Wainwright | Buy |
2020-01-08 | 繰り返されました | H.C. Wainwright | Buy |
2019-11-12 | 開始されました | SunTrust | Buy |
すべてを表示
Bioxcel Therapeutics Inc (BTAI) 最新ニュース
BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates - MSN
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript - Insider Monkey
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and Financial Adjustments - GuruFocus.com
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... By GuruFocus - Investing.com Canada
BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ... - Yahoo Finance
BioXcel Therapeutics Inc. (BTAI) Quarterly 10-Q Report - Quartz
BioXcel Therapeutics stock hits 52-week low at $0.5 By Investing.com - Investing.com Australia
BioXcel Therapeutics Reports Q3 2024 Financial Results - TipRanks
BioXcel Therapeutics stock hits 52-week low at $0.5 - Investing.com India
Earnings call: BioXcel Therapeutics reports Q3 2024 financials - Investing.com
BioXcel Therapeutics earnings beat by $0.19, revenue fell short of estimates - Investing.com Canada
BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue a - GuruFocus.com
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results - GlobeNewswire
Critical Survey: Emergent BioSolutions (NYSE:EBS) vs. BioXcel Therapeutics (NASDAQ:BTAI) - Defense World
What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings - GuruFocus.com
BioXcel Therapeutics (BTAI) Set to Announce Earnings on Thursday - Defense World
BioXcel advances trials for acute agitation treatments - Investing.com India
BioXcel advances trials for acute agitation treatments By Investing.com - Investing.com UK
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer's Dementia - The Manila Times
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of - GlobeNewswire
BioXcel's Phase 3 Breakthrough: First Patient Enrolled in Critical Agitation Treatment Trial | BTAI Stock News - StockTitan
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewswire
Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know - MSN
ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionBTAI - Marketscreener.com
BioXcel Therapeutics to Present at ThinkEquity Conference - The Manila Times
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
BioXcel Therapeutics (NASDAQ:BTAI) PT Lowered to $5.00 - Defense World
BioXcel announces defense grant to UNC to fund study for treating acute stress disorder - MSN
BioXcel Therapeutics partners with UNC for ASD trial By Investing.com - Investing.com Australia
BioXcel Therapeutics partners with UNC for ASD trial - Investing.com India
BioXcel Therapeutics Announces U.S. Department of Defense - GlobeNewswire
BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - StockTitan
BioXcel Therapeutics reports executive transition - Investing.com India
BioXcel Therapeutics reports executive transition By Investing.com - Investing.com Australia
Investing in BioXcel Therapeutics Inc (BTAI) Is Getting More Attractive - Knox Daily
BioXcel Therapeutics executive sells shares worth over $3,000 By Investing.com - Investing.com Australia
BioXcel Therapeutics CSO sells shares worth $3,946 By Investing.com - Investing.com South Africa
BioXcel Therapeutics executive sells shares worth $3,449 By Investing.com - Investing.com Australia
BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 By Investing.com - Investing.com South Africa
Bioxcel therapeutics CFO sells shares worth $3,946 By Investing.com - Investing.com Canada
Bioxcel therapeutics CFO sells shares worth $3,946 - Investing.com
BioXcel Therapeutics executive sells shares worth over $3,000 - Investing.com
BioXcel Therapeutics CSO sells shares worth $3,946 - Investing.com India
BioXcel therapeutics officer Javier Rodriguez sells shares worth $3,774 - Investing.com
BioXcel Therapeutics executive sells shares worth $3,449 - Investing.com
Bioxcel Therapeutics Inc (BTAI) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):